A Case of Disseminated and Fulminant Plasmacytomas That Developed during Bortezomib Treatment by Bae, Soo-Young et al.
 
Case Rep Oncol 2011;4:101–105 
DOI: 10.1159/000324920 
Published online: 
February 25, 2011 
© 2011 S. Karger AG, Basel 
ISSN 1662–6575 
www.karger.com/cro 
This is an Open Access article licensed under the terms of the Creative Commons Attribution-
NonCommercial-NoDerivs 3.0 License (www.karger.com/OA-license), applicable to the online 
version of the article only. Distribution for non-commercial purposes only. 
 
Je-Jung Lee, MD, PhD    Department of Hematology-Oncology 
Chonnam National University Hwasun Hospital 
160 Ilsimri, Hwasun, Jeollanamdo 519–809 (Korea) 
Tel. +82 61 379 7638, E-Mail drjejung @ chonnam.ac.kr 
 
101
   
A Case of Disseminated and 
Fulminant Plasmacytomas That 
Developed during Bortezomib 
Treatment 
Soo-Young Baea    Jae-Sook Ahna    Deok-Hwan Yanga     
Yeo-Kyeoung Kima    Jung-Joon Minb    Ho-Chun Songb    
Hee-Seung Bom
b    Yong Yeon Jeongc    Hyeoung-Joon Kima  
Je-Jung Lee
a, d 
Departments of aHematology-Oncology, bNuclear Medicine, and cRadiology, 
Chonnam National University Hwasun Hospital, Hwasun, and dThe Brain Korea 21 
Project, Center for Biomedical Human Resources at Chonnam National University 
Medical School, Gwangju, Korea 
 
Key Words 
Multiple myeloma · Bortezomib · Fulminant plasmacytoma 
 
Abstract 
Multiple myeloma is an incurable and slow growing plasma cell neoplasm. The 
introduction of new drugs has increased the number of treatment options. Bortezomib, 
the first-in-class proteasome inhibitor, has been shown to have a significant antitumor 
activity in the treatment of relapse/refractory patients with multiple myeloma. 
Additionally, plasmacytomas have shown significant response to bortezomib. In this case 
report, we describe a patient who developed disseminated and fulminant extramedullary 
plasmacytomas during combination chemotherapy treatment with bortezomib within a 
short period, after having shown clinical improvement. 
 
Introduction 
Multiple myeloma is a plasma cell malignancy characterized by slow progression. It 
follows a recurrent course that can become refractory to treatment over time. 
Combination chemotherapy including bortezomib, thalidomide, and lenalidomide is a 
highly effective salvage therapy for patients with relapsing or refractory multiple myeloma 
[1]. The development of soft tissue plasmacytomas has been reported in 15–20% of 
patients at the time of diagnosis and in an additional 15% during the course of the disease 
[2]. Many cases of relapsed multiple myeloma with large soft tissue plasmacytomas have  
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shown significant response to bortezomib [3–5]. Here, we present a rare case of 
disseminated and fulminant extramedullary plasmacytomas that developed during 
combination chemotherapy treatment with bortezomib within a short period, after 
having shown clinical improvement. 
Case Report 
In June 2009, a 60-year-old man was referred to our hospital with back pain. The laboratory values 
were as follows: hemoglobin 10.4 g/dl, creatinine 1.4 mg/dl, total calcium 11.1 mg/dl, albumin 4.8 g/dl, 
β2-microglobin 14,045.4 mg/l, free kappa-chain 96.2 mg/l, free lambda-chain 5.50 mg/l, and plasma 
cells 79% in the bone marrow aspirate. The patient was diagnosed as having multiple myeloma, kappa-
type light-chain disease. The myeloma was in the late stage, according to the International Scoring 
System (III) and Durie-Salmon stage (IIIA). The patient was treated with 4 cycles of combination 
chemotherapy consisting of cyclophosphamide, thalidomide, and dexamethasone [6], followed by an 
autologous stem cell transplantation after conditioning with melphalan in December 2009. He achieved 
a very good partial response in January 2010. In addition, he received maintenance therapy with 
thalidomide and prednisolone for 4 months. 
Due to persistent thrombocytopenia, a bone marrow biopsy was performed on the patient that 
showed diffuse infiltration of plasma cells and the free light chain was elevated, with the following 
values: kappa 171 mg/l and lambda 4.50 mg/l, with a ratio of 38. Salvage chemotherapy was performed 
with bortezomib (1.3 mg/m
2 for days 1, 4, 8, and 11), cyclophosphamide (150 mg/m
2 for days 1–4), and 
dexamethasone (20 mg/m
2 for days 1, 4, 8, and 11) [7]. After the first cycle of chemotherapy, the free 
light chain ratio returned to the normal level. Due to grade 3 asthenia, the patient could not receive 
consecutive cycles of chemotherapy. Forty days after the first cycle of chemotherapy, the patient 
complained of an oral mass in the hard palate, progressive grade 4 asthenia, and abdominal bloating. 
Computed tomography scan showed disseminated mesenteric, hepatic, and abdominal wall metastatic 
multiple nodular lesions (fig. 1a). Whole-body positron emission tomography showed similar lesions in 
addition to brain involvement (fig. 1b). Biopsies from the oral and abdominal soft tissue masses 
confirmed fulminant disseminated plasmacytomas. The patient was treated with melphalan and 
dexamethasone, but the disease progressed and he died within 4 weeks after the diagnosis of 
disseminated plasmacytomas.  
Discussion 
Multiple myeloma is a plasma cell malignancy characterized by paraproteinemia, 
immune paresis, skeletal destruction, renal dysfunction, anemia, and hypercalcemia [8]. 
The development of soft tissue plasmacytomas has been reported in 15–20% of patients at 
the time of diagnosis and in an additional 15% during the course of the disease [2]. No 
association was found between the pattern of relapse and any of the clinical characteristics 
at the time of diagnosis [9]. In transplant groups, the median relapse time of a 
plasmacytoma form was 24 months; hence, it was longer compared to classic, insidious or 
transformed diseases [9]. 
Bortezomib has recently been approved for the treatment of relapsed or refractory 
myeloma based on large studies, and these trials demonstrated 30–40% response rates, 
including 10% complete response or near complete response as a single agent in a salvage 
setting [10, 11]. Bortezomib in combination with other drugs improved the complete 
response rates up to approximately 47–50% in salvage treatment [7, 12]. In relapsed 
patients with a plasmacytoma form, bortezomib is an effective treatment agent compared 
to thalidomide [2]. Laura et al. [2] reported that bortezomib may be useful in clinical 
situations of extramedullary disease. On the contrary, Ali et al. [13] reported that  
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bortezomib might not be an effective agent for secondary extramedullary disease in 
salvage treatment for huge plasmacytoma. They explained this clinical feature with the 
concept that the tumor biology of secondary plasmacytomas may be different from the 
primary diseases.  
In our case, the patient showed a normalization of the light chain ratio after the first 
cycle of combination chemotherapy with bortezomib, but a new fulminant and 
disseminated plasmacytoma developed after 40 days. It is possible that patients relapsing 
from complete response have a more aggressive emerging clone than patients progressing 
from an insidious form to non-complete response [9]. So, our report shows the rare case 
of fulminant plasmacytomas development during bortezomib treatment within a short 
period of time.  
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Fig. 1. Appearance of disseminated extramedullary plasmacytomas. a Computed tomography scan of 
the abdomen showing numerous nodular enhancing lesions in the abdominal cavity with hepatic 
invasion. b Positron emission tomography scan showing disseminated malignant lesions in the multiple 
skeleton, brain, mediastinum, lung, abdominal cavity, retroperitoneum, liver and adrenal gland. 
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